Search
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[A33105] Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsHexafluronium
go.drugbank.com/drugs/DB00941ApprovedIt is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … [L32368] Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have
Categories: Adrenergic alpha-1 Receptor AntagonistsRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. … Fosnetupitant is the pro-drug form of netupitant [FDA label].
Categories: Substance P/Neurokinin-1 Receptor AntagonistAtomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational(NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. … The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of
Trioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnIn research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be … Like other psoralens it causes photosensitization of the skin.
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnThis modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. … A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen.